Evidence map›Paper›PMID 30691327›Full record

ArticleDrug delivery2019

Photodynamic therapy - hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity.

Nikola Plenagl, Lili Duse, Benjamin Sebastian Seitz, Nathalie Goergen, Shashank Reddy Pinnapireddy, Jarmila Jedelska, Jana Brüßler, Udo Bakowsky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nikola Plenagla Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Lili Dusea Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Benjamin Sebastian Seitza Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Nathalie Goergena Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Shashank Reddy Pinnapireddya Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Jarmila Jedelskaa Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Jana Brüßlera Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Udo Bakowskya Department of Pharmaceutics and Biopharmaceutics , University of Marburg , Marburg , Germany.
Philipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) is an established noninvasive tumor treatment. The hydrophobic natural occurring pigment hypericin shows a lot of attractive properties for the application in PDT. Hence, the administration to biological systems or patients requires the formulation in drug carriers enabling sufficient bioavailability. Therefore, free hypericin was encapsulated by the thin film hydration method or a hypericin-hydroxypropyl-β-cyclodextrin inclusion complex (Hyp-HPβCD) was incorporated by dehydration-rehydration vesicle method in either conventional or ultra-stable tetraether lipid (TEL) liposomes. The hydrodynamic diameter of the prepared nanoformulations ranged between 127 and 212 nm. These results were confirmed by atomic force microscopy. All liposomes showed a good stability under physiological conditions. TEL liposomes which tend to build more rigid bilayers, generate higher encapsulation efficiencies than their conventional counterparts. Furthermore, the suitability for intravenous application was confirmed by hemocompatibility studies resulting in a hemolytic potential less than 20% and a coagulation time less than 50 sec. The uptake of liposomal hypericin into human ovarian carcinoma cells (SK-OV-3) was confirmed using confocal microscopy and further characterized by pathway studies. It was demonstrated that the lipid composition and intraliposomal hypericin localization influenced the anti-vascular effect in the chorioallantoic membrane (CAM). While hypericin TEL liposomes exhibit substantial destruction of the microvasculature drug-in-cyclodextrin TEL liposomes showed no effect. Nevertheless, both formulations yielded severe photocytotoxicity in SK-OV-3 cells in a therapeutic dosage range. Conclusively, hypericin TEL liposomes would be perfectly suited for anti-vascular targeting while Hyp-HPβCD TEL liposomes could deliver the photosensitizer to the tumor site in a more protected manner.

Indexed as

Angiogenesis InhibitorsAnimalsAnthracenesAntineoplastic AgentsCell Line, TumorChickensChorioallantoic MembraneDose-Response Relationship, DrugErythrocytesFemaleHumansLiposomesOvarian NeoplasmsPerylenePhotochemotherapyPhotosensitizing AgentsAngiogenesis InhibitorsAnthracenesAntineoplastic AgentshypericinLiposomesPerylenePhotosensitizing AgentsantiangiogenicAntitumorhypericinliposomesphotodynamic therapy

Identifiers

PMID30691327
PMCPMC6352941
OpenAlexW2913807670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.